Show simple item record

dc.contributor.authorCoskun, Goeknil Pelin
dc.contributor.authorDjikic, Teodora
dc.contributor.authorHayal, Taha Bartu
dc.contributor.authorTurkel, Nezaket
dc.contributor.authorYelekci, Kemal
dc.contributor.authorSahin, Fikrettin
dc.contributor.authorKucukguzel, S. Guniz
dc.date.accessioned2019-07-27T12:10:23Z
dc.date.accessioned2019-07-28T09:37:52Z
dc.date.available2019-07-27T12:10:23Z
dc.date.available2019-07-28T09:37:52Z
dc.date.issued2018
dc.identifier.issn1420-3049
dc.identifier.urihttps://dx.doi.org/10.3390/molecules23081969
dc.identifier.urihttps://hdl.handle.net/20.500.12418/6205
dc.descriptionWOS: 000445295500134en_US
dc.descriptionPubMed ID: 30082676en_US
dc.description.abstractCyclooxygenase enzymes play a vital role in inflammatory pathways in the human body. Apart from their relation with inflammation, the additional involvement of COX-2 enzyme with cancer activity was recently discovered. In some cancer types the level of COX-2 enzyme is increased indicating that this enzyme could be a suitable target for cancer therapy. Based on these findings, we have synthesized some new diflunisal thiosemicarbazides and 1,2,4-triazoles and tested them against androgen-independent prostate adenocarcinoma (PC-3), colon carcinoma (HCT-116), human breast cancer (T47D), breast carcinoma (MCF7) and human embryonic kidney (HEK-293) cell lines. Specifically, the diflunisal and thiosemicarbazide functionality are combined during the synthesis of original compounds anticipating a potency enhancement. Compounds 6, 10, 15 and 16 did not show cytotoxic effects for the HEK293 cell line. Among them, compounds 15 and 16 demonstrated anticancer activity for the breast cancer cell line T47D, whereas compounds 6 and 10 which are thiosemicarbazide derivatives displayed anti-tumourigenic activity against the PC-3 cell line, consistent with the literature. However, no activity was observed for the HCT-116 cancer cell line with the tested thiosemicarbazide derivatives. Only compound 16 displayed activity against the HCT-116 cell line. Therefore, it was speculated that the diflunisal and thiosemicarbazide functionalities potentiate anticancer activity on prostate cancer and the thiosemicarbazide functionality decreases the anticancer activity of diflunisal on colon cancer cell lines. In order to gain insight into the anticancer activity and COX-2 inhibition, molecular docking studies were carried out for COX-1 and COX-2 enzymes utilizing the newly synthesized compounds 15, and 16. Both 15 and 16 showed high selectivity and affinity toward COX-2 isozyme over COX-1, which is in agreement with the experimental results.en_US
dc.description.sponsorshipScientific and Technical Research Council of Turkey (TUBITAK) [114S966]; Marie Sklodowska-Curie action, funding scheme: FP7-MC-ITN [608381]en_US
dc.description.sponsorshipThis work was supported by The Scientific and Technical Research Council of Turkey (TUBITAK), Research Fund Project Number: 114S966. The authors are grateful to Jurgen Gross from the Institute of Organic Chemistry, University of Heidelberg, for his generous help on obtaining HR-EI/FAB mass spectra of the synthesized compounds. Diflunisal was supplied by Sanovel Pharmaceutical Industry Inc, Istanbul, Turkey. Teodora Djikic kindly acknowledges "Training in Neurodegeneration, Therapeutics, Intervention and Neurorepair" project number 608381 funded by Marie Sklodowska-Curie action, funding scheme: FP7-MC-ITN.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.isversionof10.3390/molecules23081969en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectdiflunisalen_US
dc.subjectthiosemicarbazideen_US
dc.subject1,2,4-triazole-3-thioneen_US
dc.subjectanticanceren_US
dc.subjectCOX-2en_US
dc.subjectdockingen_US
dc.titleSynthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitorsen_US
dc.typearticleen_US
dc.relation.journalMOLECULESen_US
dc.contributor.department[Coskun, Goeknil Pelin] Cumhuriyet Univ, Dept Pharmaceut Chem, Fac Pharm, TR-58140 Sivas, Turkey -- [Djikic, Teodora -- Yelekci, Kemal] Kadir Has Univ, Fac Engn & Nat Sci, Dept Bioinformat & Genet, TR-34083 Istanbul, Turkey -- [Hayal, Taha Bartu -- Turkel, Nezaket -- Sahin, Fikrettin] Yeditepe Univ, Dept Genet & Bioengn, Fac Engn & Architecture, TR-34755 Istanbul, Turkey -- [Kucukguzel, S. Guniz] Marmara Univ, Dept Pharmaceut Chem, Fac Pharm, TR-34668 Istanbul, Turkeyen_US
dc.contributor.authorIDYelekci, Kemal -- 0000-0002-0052-4926; Turkel, Nezaket -- 0000-0002-4480-7282; Djikic, Teodora -- 0000-0002-6577-7465en_US
dc.identifier.volume23en_US
dc.identifier.issue8en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record